The documented U.S. regulatory record for Shenzhen Lifotronic Technology Co., Ltd. consists of one 510(k) submission in the supplied collection: K260468, received 12 February 2026 and decided 2 October 2026 as Substantially Equivalent. The applicant address in the filing is Lifotronic Tower, No. 8, Qiuzhi East Road, Guancheng Community, Guanhu Street, Longhua, Shenzhen, China. That address is a filing address, not a verified corporate headquarters. The submission covers the H100Plus Hemoglobin Testing System under product code PDJ, regulation number 862.1373, in the Clinical Chemistry panel, with a Traditional clearance type and no third-party review. [1][2][8]
The cleared device and its stated intended use
The H100Plus Hemoglobin Testing System is the device named in K260468. A company disclosure filed with the Shanghai Stock Exchange describes the product as intended for in vitro quantitative determination of glycated hemoglobin (HbA1c) in human whole blood, with a stated role in aiding diabetes diagnosis. The same disclosure lists the product as Class II, cleared 2 October 2026 under listing number K260468. The FDA record identifies the device name as H100Plus Hemoglobin Testing System and the openFDA device name field as Hemoglobin A1c Test System. [1][8]
The FDA 510(k) database entry records the applicant as Shenzhen Lifotronic Technology Co., Ltd., the decision as Substantially Equivalent (SESE), the review panel as Clinical Chemistry, and the submission as a Traditional 510(k) not reviewed by a third party. The entry also lists a subsequent product code, LCP, alongside the primary classification product code PDJ. The decision summary is linked from the database page; its contents are not reproduced here. [1][2]
Technology and configuration as published by the company
Lifotronic's product page describes the H100Plus Hemoglobin Analyzer as using high-performance liquid chromatography (HPLC) and states that it delivers HbA1c results in 45 seconds while recognizing Hb variants. The page lists a Linux-based software system, one STAT position, a 110-position sample loader, and data storage capacity. The company also states NGSP and IFCC certification for the product. These are company-published specifications, not independently verified performance data. [5]
A user manual for the H100Plus Hemoglobin Analyzer (HPLC), issued August 2025 as version A1, carries reference number 0120226 and names Shenzhen Lifotronic Technology Co., Ltd. as manufacturer at the Longhua, Shenzhen address. The manual identifies the product as a hemoglobin analyzer using HPLC. The manual's presence in a Vietnamese Ministry of Health document repository is a distribution detail; it does not establish commercial availability in any market. [4]
Filing scope and what the record does not show
The supplied collection contains one linked record, a 510(k) with decision SESE, and the sample of records is that same single entry. The decision count and the sample decision count therefore both equal one; neither figure represents total company sales, total regulatory portfolio, or safety performance. No recall records appear in the supplied sample. [1]
A company news item dated 8 October 2026 states that the H100Plus received 510(k) clearance under submission K260468, allowing marketing in the United States, and describes the clearance as a milestone in the company's HbA1c business. The Shanghai Stock Exchange disclosure dated 9 October 2026 makes a comparable statement and adds that actual U.S. sales will depend on overseas regulatory policy and market conditions, with no forecast of financial impact. Neither document reports U.S. launch, installed base, or sales results. [6][8]
Corporate identity and published company figures
Lifotronic's website states that the company was founded in Shenzhen in 2008 and lists stock code 688389. The site describes product lines including HPLC, ECLIA, and hematology systems, and lists the H100 Series Hemoglobin Analyzer and the H8 Hemoglobin Analyzer among featured products. The site also states export reach across countries and regions, hospital installations, and installed products, and cites production capability and working area figures. These are company-published claims about the broader organization, not verified attributes of the H100Plus filing. [7][9]
The FDA applicant name on K260468 matches the manufacturer name in the H100Plus user manual. The public documents do not document a separate parent, subsidiary, or brand relationship beyond the company's own use of the name Lifotronic and the Chinese-language disclosure issued under the Shenzhen Lifotronic corporate name. Any ownership structure beyond that is unknown from these sources. [1][4][8]
